about
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approachesThe rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma.A computational framework for the topological analysis and targeted disruption of signal transduction networks.von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arraysBone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.Molecular targets in the inhibition of angiogenesis.Thalidomide and its derivatives: new promise for multiple myeloma.The immune microenvironment of myelomaThalidomide and immunomodulatory drugs in the treatment of cancer.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Thalidomide: present and future in multiple myeloma.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Lenalidomide in multiple myeloma.Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myelomaInhibition of angiogenesis by extracellular protein kinase A.Emerging biological insights and novel treatment strategies in multiple myeloma.Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.The effects of thalidomide on chemotactic migration of multiple myeloma cell lines.FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.A phase II study of thalidomide in patients with brain metastases from malignant melanoma.Thalidomide and bowel perforation: four cases in one hospital.
P2860
Q24806367-42C4923B-DCF6-4DE1-85AE-446BF7974408Q33685257-F3E3759A-A9E3-4A70-826D-B8579BAE8730Q33865839-16A93EC5-3973-4108-B743-0FEF6AC69C14Q34034447-69066674-901D-4980-8EA5-A5C8BCE18074Q34680360-7AD908FF-A31F-4C9D-9A77-205A059119B6Q34784862-AD11F034-25A7-444A-8E0C-CAA974A5333CQ35175287-D0A66A6D-8ED4-425D-8363-C32B34992A4BQ35186667-8B8DB0AE-589F-4364-9B42-B5D813E0BDBBQ35569462-FC292B34-022B-4D88-B697-A67D6B5D36CFQ35603152-AD37DF05-D922-4438-82E5-F33A1B88E14FQ36040871-AB1EE590-885B-4929-BC23-4AE3A67CB08BQ36061821-6CC8200B-1639-4377-AC6E-AD626FFF37BBQ36066131-087FECBF-41E4-4FDA-AC3B-2ACB342FF4D0Q36171864-73603613-105D-41B0-8469-B29226432A8CQ36573818-FC4ACA2F-9594-49FA-B140-469ED3014320Q37090630-0FC9A5C2-3CBA-4BD9-AA9D-9C8B59A65C71Q37163265-9C71A622-F5E4-476D-9629-A929499852ADQ37270000-C494D0A1-B5C0-442B-BB3B-7C105FB81E13Q38037600-202EECB7-CBE2-4378-9A15-BF49BD986183Q38815319-0FAED2C6-D3B4-496C-87A1-EBBFD210335FQ39982583-90570E7B-7E8D-451D-8AD2-6725B7E832FAQ40314855-D9BB4B66-078D-46B5-81D8-85F3EB2B0193Q44826295-6FD79557-98BF-4D01-9952-6C060897EB00Q46496647-1D1213B5-77A4-4B06-A80F-0BDA6CFE7611Q46879750-D981F768-4BCD-46B2-A685-B9396207BD28
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Thalidomide: emerging role in cancer medicine.
@ast
Thalidomide: emerging role in cancer medicine.
@en
Thalidomide: emerging role in cancer medicine.
@nl
type
label
Thalidomide: emerging role in cancer medicine.
@ast
Thalidomide: emerging role in cancer medicine.
@en
Thalidomide: emerging role in cancer medicine.
@nl
prefLabel
Thalidomide: emerging role in cancer medicine.
@ast
Thalidomide: emerging role in cancer medicine.
@en
Thalidomide: emerging role in cancer medicine.
@nl
P1476
Thalidomide: emerging role in cancer medicine.
@en
P2093
Teru Hideshima
P304
P356
10.1146/ANNUREV.MED.53.082901.104043
P577
2002-01-01T00:00:00Z